Combined treatment with anti‐PSMA CAR NK‐92 cell and anti‐PD‐L1 monoclonal antibody enhances the antitumour efficacy against castration‐resistant prostate cancer

202258 citationsJournal Articlegold Open Access

Authors

Fangming Wang · Chinese Academy of Medical Sciences & Peking Union Medical College

Liyuan Wu · Chinese Academy of Medical Sciences & Peking Union Medical College

Le Yin · Allied Innovative Systems (United States)

Hui Shi · Peking University

Yuchun Gu · Aston University

Nianzeng Xing · Shanxi Medical University

Abstract

Combined treatment with CAR NK-92 and anti-PD-L1 mAb improved the antitumour efficacy against CRPC, which is of extraordinary translational value in the clinical treatment of CRPC.

Topics & Keywords

CAR-T cell therapy research Cancer Immunotherapy and Biomarkers Immunotherapy and Immune Responses

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical and Translational Medicine

Volume 12, Issue 6, pp. e901-e901

DOI: 10.1002/ctm2.901

Field-Weighted Citation Impact: 6.07